×
The submission system is temporarily under maintenance. Please send your manuscripts to
Go to Editorial ManagerOne of the most interesting pharmaceutical drug delivery systems with minimally invasive technique are Microneedles. In the recent years, many researchers have concluded that Microneedles can be a leading method in the future. As a drug delivery system, Microneedles can improve drug delivery by avoiding many barriers that were linked with the conventional system, these unique properties could make Microneedles widely used. The primary mechanism for improving drug delivery to the targeted site with minimal complications is by creating micro-sized pores in the skin layer. The growing interest of Microneedles in biomedical and pharmaceutical research is obtained by easy delivery of active ingredient with low invasive technique. Vaccines, peptides, and hormones are examples of molecules delivered by Microneedles. In this review, we will discuss Microneedles efficiency as drug delivery carriers, fabrication materials, and several related patents
Drug delivery methods have evolved to improve therapeutic outcomes, patient compliance, and therapy outcomes. This review examines the historical progression of drug delivery strategies, current innovations, and emerging trends shaping the future of therapeutic approaches. Traditional methods of giving medications, like oral and injection routes, had many problems, such as low bioavailability and systemic side effects. This review looks at how drug delivery systems have changed throughout several drug development eras. It focuses on new developments such as nanotechnology-based delivery, biologics, and the creation of smart drug delivery systems. This review highlights breakthroughs in controlled-release systems, nanocarriers, transdermal patches, and implantable drug-delivery devices, comparing both conventional and modern strategies. Further, advances in microencapsulation technology, gene therapy delivery strategies, and AI-assisted drug formulation are examined in the context of precision and efficacy. These innovations reflect a paradigm shift toward precision medicine with personalized drug delivery strategies minimizing side effects while maximizing therapeutic outcomes. Importantly, nanomedicine and biological therapies have successfully addressed critical challenges of drug stability, bioavailability, and drug delivery mechanisms for controlled release devices
ABSTRACT Psoriasis (PSO) is an immune-mediated dermatological disorder marked by thick, erythematous, scaly plaques resulting from rapid, excessive cellular growth. Anti-inflammatory agents, immunosuppressant’s, and additional pharmaceuticals serve as the principal therapeutic strategy for psoriasis to alleviate symptoms, diminish inflammation, and inhibit the proliferation and division of epidermal cells. Nevertheless, these drugs generally include disadvantages that impose significant physiological and pathological burdens on patients, including inadequate targeting, brief half-lives, limited absorption rates, and severe toxic side effects. Researchers have recently concentrated significant effort on employing delivery systems for the topical administration of drugs to affected psoriatic skin regions. These systems increase pharmacological efficacy, stability, and penetration. More therapeutic concepts for the treatment of PSO are made possible by the ongoing development of numerous multifunctional topical delivery technologies. This publication reviews various delivery strategies, including hydrogels, nanoparticles, microneedles, micelles, dendrimers, liposomes, nanoemulsions, and vesicles, for topical therapy of PSO and delineates their current developmental status in clinical treatment. It is expected to facilitate the progression of PSO treatment methodologies and provide a benchmark for the development of novel topical delivery systems.
Floating Drug Delivery Systems (FDDS) is a very recent approach in the development of oral drug delivery systems, which can be employed to control the gastric emptying time of filled device for both sustained and controlled release (CR) preparations, to locate the CR in a particular site, to minimize the drug loss and to improve drug delivery. These types of systems have a low density, are buoyant in gastric fluid, maintain longer residence time in the stomach with controlled drug release. FDDS can be prepared in tablets, capsules, powders, granules, films and microspheres and are especially valuable when dealing with highly water-soluble drugs with short halflife, having absorption window low in the gut or having instability at intestinal pH. There are several types of FDDS such as effervescent, non-effervescent, raft-forming, the hydrodynamically balanced and the inflatable system that uses different ways to float and consequent modification of release. Their performance is highly dependent upon physiological parameters, such as gastric pH, motility, meal content, age, and body position. FDDS have various advantages such as increased bioavailability, rapid onset of action, a lower frequency of dose administration, better patient compliance, and long site-specific action in the stomach, which is useful in the case of gastroesophageal reflux disease (GERD) and peptic ulcers. Nevertheless, gastric emptying variability and complexity of the formulation still pose obstacles. Newer excipients and polymers and newer carriers will continue to improve these systems, making FDDS a potential weapon for future gastroprotective and controlled-release therapies.